was supported by a Takeda Science Foundation 2019 Medical Research Grant and Japan Science and Technology Agency PRESTO (18069571)
Resmetirom followed with a significant increase in risk, presenting an RR of 1.77 (95% CI: 1.08 to 2.88, p = 0.0223)
During the full time period (2018 2024), 70.9% of GLP-1 RA prescriptions had a dispense within 60 days of their prescription (e.g., were initiated within 60 days)
This enhanced efficacy is due to semaglutides unique ability to strongly bind to GLP-1 receptors, thereby effectively controlling appetite, slowing digestion, and helping patients feel full longer
Semaglutide administration led to a decrease in BMD: 2.1% in the lumbar spine ( p = 0.01), 2.6% in the total hip ( p = 0.001), and 1.5% in the tibial volumetric BMD ( p = 0.003)
Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six teratology information services
